(CercleFinance.com) – Transgene shares are on the rise on the Paris Stock Exchange on Monday following the presentation of data deemed ‘promising’ at the annual ASCO cancer conference.
In a press release, the ‘biotech’ specifies that these new preliminary data have been obtained in the first patients treated in two phase I multicenter trials evaluating its personalized therapeutic vaccine TG4050 in ovarian cancer and head and neck cancer. neck.
Transgene demonstrates efficacy in inducing immune responses and early signs of clinical activity, with results suggesting that TG4050 has the potential to prolong the remission period.
In this context, the vaccine could provide clinical benefit by controlling residual disease, as stimulation of the immune system by the vaccine has been associated with disease regression, the company continues.
‘The results obtained so far suggest that TG4050 has the potential to prolong the period of remission and offer new hope to cancer patients, especially in patients at high risk of cancer relapse and for whom the medical need is particularly high”, react for their part the analysts of Invest Securities.
Transgene underlines that these data, presented yesterday in Chicago in person, will be decisive for designing a Phase II trial which could begin as early as 2023.
On the Paris Stock Exchange, the Transgene share rose by almost 2% on Monday morning following these announcements, after having risen by more than 6% for a time.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about TRANSGENE in real time: